Bellicum Pharmaceuticals, Inc.
BLCMNASDAQHealthcare
$0.07
$-0.01(-6.68%)
Market Cap$778326
P/E Ratio—
52W High$1.31
52W Low$0.06
Bellicum Pharmaceuticals, Inc. (BLCM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BLCM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.50M | $6.20M | $0.50M | $7.14M | $1.12M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $1.50M | $6.20M | $0.50M | $7.14M | $1.12M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $22.76M | $23.58M | $39.05M | $64.53M | $71.15M |
| G&A Expenses | $5.72M | $7.01M | $15.53M | $29.97M | $25.43M |
| Total Operating Expenses | $28.48M | $30.59M | $54.58M | $94.51M | $96.59M |
| Operating Income | ($26.98M) | ($24.87M) | ($51.69M) | ($87.36M) | ($95.47M) |
| Operating Margin %(computed) | — | -401.06% | — | — | — |
| Interest Income | $0.00M | $0.03M | $0.39M | $1.35M | $1.64M |
| Interest Expense | $0.00M | $0.00M | $2.66M | $4.28M | $4.20M |
| Income Before Tax | ($24.97M) | ($9.71M) | ($7.72M) | ($112.48M) | ($98.04M) |
| Income Tax Expense | $0.00M | ($0.13M) | $0.90M | $13.62M | $0.00M |
| Net Income | ($24.97M) | ($9.58M) | ($8.62M) | ($126.09M) | ($98.04M) |
| Net Margin %(computed) | — | -154.48% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.81 | $-0.83 | $-1.50 | $-26.92 | $-24.37 |
| Wtd Avg Shares | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M |
| EBITDA | ($26.98M) | ($24.35M) | $2.39M | ($87.36M) | ($95.47M) |
| EBITDA Margin %(computed) | — | -392.73% | 478.20% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Bellicum Pharmaceuticals, Inc. data
About Bellicum Pharmaceuticals, Inc. (BLCM) Income Statement
Bellicum Pharmaceuticals, Inc. (BLCM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, BLCM reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.02B) — a net profit margin of -1664.87%.
Frequently asked questions
BLCM · 4 questionsBellicum Pharmaceuticals, Inc. (BLCM) reported revenue of $0.00B for 2022, down 75.8% year-over-year.
BLCM revenueBLCM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09